Rita Steeves
ImmunoGen, Inc.
23 Papers
342 Citations
Rita Steeves is an academic researcher from ImmunoGen, Inc.. The author has contributed to research in topics: Maytansinoid & Ricin. The author has an hindex of 9, co-authored 23 publications. Previous affiliations of Rita Steeves include Janssen Pharmaceutica.
Chat about Author
Papers
Semisynthetic maytansine analogues for the targeted treatment of cancer.
Wayne C. Widdison,Sharon D. Wilhelm,Emily E. Cavanagh,Kathleen R. Whiteman,Barbara A. Leece,Yelena Kovtun,Victor S. Goldmacher,Hongsheng Xie,Rita Steeves,Robert J. Lutz,Robert Yongxin Zhao,Lintao Wang,Walter A. Blattler,Ravi V. J. Chari +13 more
TL;DR: The targeted delivery of a series of new maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.
362
Patent
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
Rita Steeves,Robert J. Lutz,Ravi V. J. Chari,Hongsheng Xie,Yelena Kovtun +4 more
- 12 Oct 2004
TL;DR: In this article, a method for targeting maytansinoids to a selected cell population is presented, which involves contacting a cell population or tissue suspected of containing the selected cell populations with a cell-binding agent maytsinoid conjugate, wherein one or more maytANSsinoids is covalently linked to the cell binding agent via a non-cleavable linker.
218
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage
Brenda Kellogg,Lisa M. Garrett,Yelena Kovtun,Katharine C. Lai,Barbara A. Leece,Michael L. Miller,Gillian Payne,Rita Steeves,Kathleen R. Whiteman,Wayne C. Widdison,Hongsheng Xie,Rajeeva Singh,Ravi V. J. Chari,John M. Lambert,Robert J. Lutz +14 more
TL;DR: Evidence is provided that bystander killing of neighboring nontargeted tumor cells by diffusible cytotoxic metabolites produced from target cell processing of disulfide-linked antibody-maytansinoid conjugates may be one additional factor contributing to the activity of these conjugate in vivo.
218
•Journal Article
Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo Efficacy of an Immunoconjugate
Sarajane Ross,Susan D. Spencer,Ilona Holcomb,Christine Tan,Jo Anne Hongo,Brigitte Devaux,Linda Rangell,Gilbert A. Keller,Peter Schow,Rita Steeves,Robert J. Lutz,Gretchen Frantz,Kenneth J. Hillan,Franklin Peale,Patti Tobin,David A. Eberhard,Mark A. Rubin,Laurence A. Lasky,Hartmut Koeppen +18 more
TL;DR: In this article, the authors conducted an expression analysis of prostate stem cell antigen (PSCA) in normal urogenital tissues, using isotopic in situ hybridization on tissue microarrays.
191
Patent
Anti-integrin immunoconjugates, methods and uses
Qiming Chen,Mohit Trikha,Robert J. Lutz,Rita Steeves,Godfrey W. Amphlett +4 more
- 30 Nov 2005
TL;DR: In this paper, the authors proposed conjugates of anti-integrin specific antibodies with cytotoxic compounds for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue.
49